Biotech catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
November 2026
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Nov 25, 2026Sponsor estimate | NCT07859007A Study to Assess the Potential CYP3A Induction Effect of Brensocatib on the Pharmacokinetics (PK) of Midazolam in Healthy ParticipantsInsmed Incorporated · Healthy Volunteers | INSMLead | Phase 1 | Not yet recruiting | Locked | Locked | Locked |
| Nov 25, 2026Sponsor estimate | NCT07928037A Study of Real-world Effectiveness of 177Lu-PSMA-617 With and Without Concurrent Androgen Receptor Pathway Inhibitors in Metastatic...Novartis Pharmaceuticals · Metastatic Castration-Resistant Prostate Cancer | NVSLead | No phase registered | Not yet recruiting | Locked | Locked | Locked |
| Nov 30, 2026Sponsor estimate | NCT07680907A Real World Study of Participants With Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor Mutation (EGFRm)Janssen-Cilag Farmaceutica Ltda. · Carcinoma, Non-Small-Cell Lung | JNJLead | No phase registered | Not yet recruiting | Locked | Locked | Locked |
- Primary completion Nov 25, 2026Sponsor estimatePhase 1NCT07859007A Study to Assess the Potential CYP3A Induction Effect of Brensocatib on the Pharmacokinetics (PK) of Midazolam in Healthy ParticipantsInsmed Incorporated · Healthy VolunteersNot yet recruitingINSMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 25, 2026Sponsor estimateNo phase registeredNCT07928037A Study of Real-world Effectiveness of 177Lu-PSMA-617 With and Without Concurrent Androgen Receptor Pathway Inhibitors in Metastatic...Novartis Pharmaceuticals · Metastatic Castration-Resistant Prostate CancerNot yet recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimateNo phase registeredNCT07680907A Real World Study of Participants With Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor Mutation (EGFRm)Janssen-Cilag Farmaceutica Ltda. · Carcinoma, Non-Small-Cell LungNot yet recruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
December 2026
- Primary completion Dec 2026Sponsor estimatePhase 1/Phase 2NCT06258018Niraparib and Temozolomide in Patients GlioblastomaArmando Santoro, MD · Glioma, MalignantNot yet recruitingGSKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1NCT07163481A Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic...Hunan Cancer Hospital · Stage IV (Metastatic) Breast CancerNot yet recruitingGILDCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1NCT07430059Safety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide ImplantVivani Medical, Inc · Obesity & OverweightNot yet recruitingVANILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1NCT07889193Phase I Clinical Trial of Trivalent Inactivated Split Influenza Virus Vaccine (MDCK Cell)Sinovac Biotech Co., Ltd · Seasonal InfluenzaNot yet recruitingSVALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 1, 2026Sponsor estimateNo phase registeredNCT05298293Electronic MonitorIng of Events for dIffuse Large b Cell LYmphomaWeprom · Diffuse Large B Cell LymphomaNot yet recruitingINCYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 1, 2026Sponsor estimateNo phase registeredNCT07400861Study of Min-Max APAP Recommender ToolResMed · Obstructive Sleep Apnea (OSA)Not yet recruitingRMDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 1, 2026Sponsor estimatePhase 4NCT07564310INFORMing Patients With Oximetry Data to Improve MAD EngagementResMed · Obstructive Sleep Apnea (OSA)Not yet recruitingRMDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 15, 2026Sponsor estimateNo phase registeredNCT07906418BCMA Polymorphisms in Patients With Multiple MyelomaBaşakşehir Çam & Sakura City Hospital · Multiple MyelomaNot yet recruitingJNJCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 24, 2026Sponsor estimatePhase 1NCT07915947LTG-321 - Itraconazole Drug-drug Interaction (DDI) StudyLatigo Biotherapeutics · PK Drug-drug Interaction StudyNot yet recruitingLTGOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2026Sponsor estimatePhase 3NCT07055295Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Pre-exposure Prophylaxis RegimenSinovac Biotech Co., Ltd · RabiesNot yet recruitingSVALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2026Sponsor estimateNo phase registeredNCT07914972Treatment Pattern and Patient Outcomes Among Stage I-II Unresected NSCLC PatientsAstraZeneca · Non-small Cell Lung CancerNot yet recruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 2NCT06449625Semaglutide in Auto-HSCTKlaus Gottlob Müller · Intestinal MucositisNot yet recruitingNVOCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 2NCT06528483Bladder Preservation With Sacituzumab Govitecan + Zimberelimab for Muscle-Invasive Bladder CancerFondazione IRCCS Istituto Nazionale dei Tumori, Milano · Bladder CancerNot yet recruitingGILDCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimateNo phase registeredNCT06635421The Expand Study-Pharmacist Administered Long Acting Cabotegravir + Rilpivirine to Expand Access for People With HIVMetroHealth Medical Center · HIV I InfectionNot yet recruitingGSKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 4NCT06830668Same-Day Restart of B/F/TAF in HIV Patients After NNRTI DiscontinuationNational Center for AIDS/STD Control and Prevention, China CDC · HIV InfectionNot yet recruitingGILDCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimateNo phase registeredNCT07055139Digital Aftercare for Wrist and Clavicle FracturesLuzerner Kantonsspital · Distal Radius FractureNot yet recruitingJNJCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
January 2027
- Primary completion Jan 2027Sponsor estimatePhase 1/Phase 2NCT06590545Anti-CD 19 CAR-T Cell Therapy in Patients With ANCA VasculitisDavid Simon · ANCA-IgG-positive ANCA Associated VasculitisNot yet recruitingKYTXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2027Sponsor estimateNo phase registeredNCT07877805Merlin Expanded ECG NSRAbbott Medical Devices · Heart FailureNot yet recruitingABTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 1, 2027Sponsor estimatePhase 4NCT06271681Evaluation of PCV21 Vaccination Among PPSV23-experienced, Immunocompromised Elderly VeteransVA Sierra Nevada Health Care System · Pneumococcal VaccinesNot yet recruitingMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 1, 2027Sponsor estimateNo phase registeredNCT07945548A Study Characterizing the Elevated Liver Enzymes in Ribociclib Treated HR+ HER2- Advanced Breast Cancer Patients Using a Machine...Novartis Pharmaceuticals · Breast CancerNot yet recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 5, 2027Sponsor estimateNo phase registeredNCT07770074A Real-World Study of Second-line Therapies Among Radioiodine-refractory Differentiated Thyroid Cancer (RAI-R DTC) PatientsNovartis Pharmaceuticals · Radioiodine-refractory Differentiated Thyroid CancerNot yet recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 9, 2027Sponsor estimateNo phase registeredNCT07793175Bridging Clinical Trial of EV71 Vaccine in Vietnamese ChildrenSinovac Biotech Co., Ltd · Hand, Foot, and Mouth Disease (HFMD)Not yet recruitingSVALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 18 more in this window; the full list is part of TrialScanner.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.